CARSGEN-B (02171) announces its interim results with a net loss of 75.48 million yuan, a year-on-year decrease of 78.53%.
Kozi Pharmaceutical-B (02171) announced its mid-term performance for 2025, with a profit of 50.961 million RMB, a year-on-year increase...
CARSGEN-B (02171) announced its mid-term performance for 2025, with a profit of 50.961 million yuan, an increase of 703.8% year-on-year; a gross profit of 29.369 million yuan, an increase of approximately 17.16 times year-on-year; a net loss of 75.483 million yuan, which narrowed by 78.53% year-on-year; and a loss per share of 0.14 yuan.
The announcement stated that the decrease in losses was mainly due to a reduction in research and development expenses, a reduction in administrative expenses, an increase in net foreign exchange gains, and an increase in gross profit.
Related Articles

MINSHENG EDU (01569): HKIAC makes a partial ruling ordering the respondent to fulfill the relevant terms of the SPA.

BRAINAURORA-B (06681) signs a brain health digital AI technology service cooperation agreement with Macau Mirror Lake Hospital.

China Securities Co., Ltd.: The spring market is expected to continue after the Spring Festival, it is recommended to hold onto stocks during the festival.
MINSHENG EDU (01569): HKIAC makes a partial ruling ordering the respondent to fulfill the relevant terms of the SPA.

BRAINAURORA-B (06681) signs a brain health digital AI technology service cooperation agreement with Macau Mirror Lake Hospital.

China Securities Co., Ltd.: The spring market is expected to continue after the Spring Festival, it is recommended to hold onto stocks during the festival.

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


